Corrigendum to “Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV” (10.1038/mt.2014.177));Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 99-107

  Mazzacurati, Lucia ^a,b   Marzulli, Marco ^a   Reinhart, Bonnie ^a   Miyagawa, Yoshitaka ^a   Uchida, Hiroaki ^c   Goins, William F ^a   Li, Aofei ^a,d   Kaur, Balveen ^e   Caligiuri, Michael ^f,g   Cripe, Timothy ^f   Chiocca, Nino ^h   Amankulor, Nduka ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a   Grandi, Paola ^a,i  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d Ohio State University ^*  (China)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HERPESVIRUS VECTOR; MICRORNA 124; ONCOLYTIC HERPES VIRUS; 3' UNTRANSLATED REGION; EGFR PROTEIN, HUMAN; HERPES SIMPLEX VIRUS, TYPE 1 PROTEIN ICP4; IMMEDIATE EARLY PROTEIN; MICRORNA; MIRN124 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG SAFETY; DRUG TARGETING; GENE; GENE EXPRESSION; GENE INSERTION; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; ICP4 GENE; MOUSE; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOGENESIS; PRIMARY TUMOR; RNA SEQUENCE; TREATMENT RESPONSE; VALIDATION STUDY; VIRUS ATTENUATION; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN NEOPLASMS; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GLIA; HEK293 CELL LINE; HERPES SIMPLEX VIRUS 1; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; MOLECULAR GENETICS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALIA; MUS MUSCULUS; SIMPLEXVIRUS;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHROMOSOMES, ARTIFICIAL, BACTERIAL; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HEK293 CELLS; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, NUDE; MICRORNAS; MOLECULAR SEQUENCE DATA; NEUROGLIA; NEURONS; ONCOLYTIC VIROTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920601317     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.216     Document Type: Erratum

References (44)

1. Parker, JN, Bauer, DF, Cody, JJ and Markert, JM (2009). Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6: 558-569.
2. Grandi, P, Peruzzi, P, Reinhart, B, Cohen, JB, Chiocca, EA and Glorioso, JC (2009). Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother 9: 505-517.
3. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874.
4. Todo, T (2008). Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 13: 2060-2064.
5. Uchida, H, Marzulli, M, Nakano, K, Goins, WF, Chan, J, Hong, CS et al. (2013). Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther 21: 561-569.
6. Gaur, A, Jewell, DA, Liang, Y, Ridzon, D, Moore, JH, Chen, C et al. (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67: 2456-2468.
7. Karsy, M, Arslan, E and Moy, F (2012). Current Progress on understanding microRNAs in glioblastoma multiforme. Genes Cancer 3: 3-15.
8. Riddick, G and Fine, HA (2011). Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 7: 439-450.
9. Kumar, MS, Lu, J, Mercer, KL, Golub, TR and Jacks, T (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-677.
10. Tischer, BK, von Einem, J, Kaufer, B and Osterrieder, N (2006). Two-step red-mediated recombination for versatile high-effciency markerless DNA manipulation in Escherichia coli. Biotechniques 40: 191-197.
11. Gierasch, WW, Zimmerman, DL, Ward, SL, Vanheyningen, TK, Romine, JD and Leib, DA (2006). Construction and characterization of bacterial artifcial chromosomes containing HSV-1 strains 17 and KOS. J Virol Methods 135: 197-206.
12. Bennett, JJ, Delman, KA, Burt, BM, Mariotti, A, Malhotra, S, Zager, J et al. (2002). Comparison of safety, delivery, and effcacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 9: 935-945.
13. Szymczak, AL and Vignali, DA (2005). Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 5: 627-638.
14. Doronina, VA, Wu, C, de Felipe, P, Sachs, MS, Ryan, MD and Brown, JD (2008). Site-specifc release of nascent chains from ribosomes at a sense codon. Mol Cell Biol 28: 4227-4239.
15. Uchida, H, Chan, J, Goins, WF, Grandi, P, Kumagai, I, Cohen, JB et al. (2010). A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol 84: 12200-12209.
16. Uchida, H, Chan, J, Shrivastava, I, Reinhart, B, Grandi, P, Glorioso, JC et al. (2013). Novel mutations in gB and gH circumvent the requirement for known gD receptors in herpes simplex virus 1 entry and cell-to-cell spread. J Virol 87: 1430-1442.
17. Cao, X, Pfaff, SL and Gage, FH (2007). A functional study of miR-124 in the developing neural tube. Genes Dev 21: 531-536.
18. Fujioka, N, Akazawa, R, Ohashi, K, Fujii, M, Ikeda, M and Kurimoto, M (1999). Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J Virol 73: 2401-2409.
19. Manickan, E, Rouse, RJ, Yu, Z, Wire, WS and Rouse, BT (1995). Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. J Immunol 155: 259-265.
20. Sethi, KK, Omata, Y and Schneweis, KE (1983). Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specifc and H-2-restricted cytotoxic T lymphocytes. J Gen Virol 64 (Pt 2): 443-447.
21. Currier, MA, Gillespie, RA, Sawtell, NM, Mahller, YY, Stroup, G, Collins, MH et al. (2008). Effcacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 16: 879-885.
22. Hong, CS, Fellows, W, Niranjan, A, Alber, S, Watkins, S, Cohen, JB et al. (2010). Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther 17: 1200-1205.
23. Lee, CY, Rennie, PS and Jia, WW (2009). MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res 15: 5126-5135.
24. Kelly, EJ, Nace, R, Barber, GN and Russell, SJ (2010). Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 84: 1550-1562.
25. Cawood, R, Chen, HH, Carroll, F, Bazan-Peregrino, M, van Rooijen, N and Seymour, LW (2009). Use of tissue-specifc microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 5: e1000440.
26. Ylösmäki, E, Hakkarainen, T, Hemminki, A, Visakorpi, T, Andino, R and Saksela, K (2008). Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specifc microRNA. J Virol 82: 11009-11015.
27. Barnes, D, Kunitomi, M, Vignuzzi, M, Saksela, K and Andino, R (2008). Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4: 239-248.
28. Zhang, Y, Chao, T, Li, R, Liu, W, Chen, Y, Yan, X et al. (2009). MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med (Berl) 87: 43-51.
29. Shi, L, Cheng, Z, Zhang, J, Li, R, Zhao, P, Fu, Z et al. (2008). hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236: 185-193.
30. Silber, J, Lim, DA, Petritsch, C, Persson, AI, Maunakea, AK, Yu, M et al. (2008). miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14.
31. Maiorano, NA and Mallamaci, A (2010). The pro-differentiating role of miR-124: indicating the road to become a neuron. RNA Biol 7: 528-533.
32. Wei, J, Wang, F, Kong, LY, Xu, S, Doucette, T, Ferguson, SD et al. (2013). miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 73: 3913-3926.
33. Lavon, I, Zrihan, D, Granit, A, Einstein, O, Fainstein, N, Cohen, MA et al. (2010). Gliomas display a microRNA expression profle reminiscent of neural precursor cells. Neuro Oncol 12: 422-433.
34. Karpowicz, P, Willaime-Morawek, S, Balenci, L, DeVeale, B, Inoue, T and van der Kooy, D (2009). E-cadherin regulates neural stem cell self-renewal. J Neurosci 29: 3885-3896.
35. Katoh, Y and Katoh, M (2008). Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med 22: 271-275.
36. Ocaña, OH and Nieto, MA (2008). A new regulatory loop in cancer-cell invasion. EMBO Rep 9: 521-522.
37. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD et al.; Cancer Genome Atlas Research Network. (2010). Integrated genomic analysis identifes clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
38. Nduom, EK, Hadjipanayis, CG and Van Meir, EG (2012). Glioblastoma cancer stemlike cells: implications for pathogenesis and treatment. Cancer J 18: 100-106.
39. He, J, Liu, Y and Lubman, DM (2012). Targeting glioblastoma stem cells: cell surface markers. Curr Med Chem 19: 6050-6055.
40. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
41. Xia, H, Cheung, WK, Ng, SS, Jiang, X, Jiang, S, Sze, J et al. (2012). Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 287: 9962-9971.
42. Macdonald, SJ, Mostafa, HH, Morrison, LA and Davido, DJ (2012). Genome sequence of herpes simplex virus 1 strain KOS. J Virol 86: 6371-6372.
43. Kaji, K, Norrby, K, Paca, A, Mileikovsky, M, Mohseni, P and Woltjen, K (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458: 771-775.
44. Krisky, DM, Marconi, PC, Oligino, T, Rouse, RJ, Fink, DJ and Glorioso, JC (1997). Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 4: 1120-1125.